Isatuximab Plus Carfilzomib: A New Standard for Relapsed/Refractory Myeloma? – ASH Clinical News
Isatuximab Plus Carfilzomib: A New Standard for Relapsed/Refractory Myeloma? – Multiple Myeloma, On Location, Other Meetings – ASH Clinical News
Related Articles
ASH Clinical News: May 2024 From the Desk Of…
ASH Clinical News Editor-in-Chief Aaron Gerds, MD, previews the upcoming May issue of the magazine. Highlights include a feature on the practice of “bagging”…
In Full Bloom: A Closer Look at Open-Access Publishing | ASH Clinical News | American Society of Hematology
Naseema Gangat, MBBS, is a professor of medicine in the Division of Hematology at Mayo Clinic in Rochester, Minnesota. In the last two decades, open-access…
Apixaban No Better Than Aspirin for Treatment of Embolic Stroke of Undetermined Source | ASH Clinical News | American Society of Hematology
Leah Lawrence is a freelance health writer and editor based in Delaware. Use of the direct oral anticoagulant (DOAC) apixaban was not superior to cardiac…
Pulling Back the Curtain: Ruemu Ejedafeta Birhiray, MD | ASH Clinical News | American Society of Hematology
Mary Ellen Schneider is a medical journalist based in Setauket, New York. Ruemu E. Birhiray, MD, is a hematologist/oncologist and clinical investigator at Hematology Oncology…
High-Dose Oral Vitamin A Before HCT May Reduce GVHD in Children | ASH Clinical News | American Society of Hematology
Katie Robinson is a medical writer based in New York. Compared with placebo, a high dose of oral vitamin A given before a hematopoietic cell…
FDA, EMA to Review Hemophilia Treatment | ASH Clinical News | American Society of Hematology
The U.S. Food and Drug Administration (FDA) accepted Pfizer’s Biologics License Application for marstacimab as treatment for hemophilia A or hemophilia B in patients without…
Letter to the Editor: Choosing an Anticoagulant in Patients With APS | ASH Clinical News | American Society of Hematology
In the December 2023 issue of “You Make the Call,” Shruti Chaturvedi, MBBS, MS, discussed treatment options for a female patient presenting with a left…
Belantamab Mafodotin Induces Durable Response When Combined With Pom-Dex, Despite Ocular Effects | ASH Clinical News | American Society of Hematology
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. The anti-BCMA belantamab mafodotin (belamaf), plus pomalidomide and dexamethasone (Pd), produced durable…
Privacy Improbable | ASH Clinical News | American Society of Hematology
Jill Sederstrom is a journalist based in Kansas City. For decades, health systems across the country have been devoting significant resources to make the shift…
Validate User
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will…